GLI1 and cancer: These findings highlight that mPEG5kDa-cholane/GlaB is a promising candidate for clinical studies for the treatment of HH-dependent cancers and nowadays is the most encouraging drug delivery formulation for GLI inhibitors efficient in counteracting SHH-MB growth in preclinical investigation.